Supplemental references:

1. Børresen AL, Hovig E, Smith-Sørensen B, et al (1991) Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A 88:8405–8409. https://doi.org/10.1073/pnas.88.19.8405

2. Coles C, Condie A, Chetty U, et al (1992) p53 mutations in breast cancer. Cancer Res 52:5291–5298

3. Sommer SS, Cunningham J, McGovern RM, et al (1992) Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 84:246–252. https://doi.org/10.1093/jnci/84.4.246

4. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S (1993) p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84:394–401. https://doi.org/10.1111/j.1349-7006.1993.tb00149.x

5. Andersen TI, Holm R, Nesland JM, et al (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68:540–548. https://doi.org/10.1038/bjc.1993.383

6. Thorlacius S, Börresen AL, Eyfjörd JE (1993) Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637–1641

7. Cornelis RS, van Vliet M, Vos CB, et al (1994) Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200–4206

8. Blaszyk H, Vaughn CB, Hartmann A, et al (1994) Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet (London, England) 343:1195–1197. https://doi.org/10.1016/s0140-6736(94)92403-1

9. Umekita Y, Kobayashi K, Saheki T, Yoshida H (1994) Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn J Cancer Res 85:825–830. https://doi.org/10.1111/j.1349-7006.1994.tb02954.x

10. Tsuda H, Hirohashi S (1994) Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J cancer 57:498–503. https://doi.org/10.1002/ijc.2910570410

11. Saitoh S, Cunningham J, De Vries EM, et al (1994) p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9:2869–2875

12. Hartmann A, Rosanelli G, Blaszyk H, et al (1995) Novel pattern of P53 mutation in breast cancers from Austrian women. J Clin Invest 95:686–689. https://doi.org/10.1172/JCI117714

13. Shiao YH, Chen VW, Scheer WD, et al (1995) Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55:1485–1490

14. Hartmann A, Blaszyk H, McGovern RM, et al (1995) p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10:681–688

15. Karameris AM, Worthy E, Gorgoulis VG, et al (1995) p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material. J Pathol

176:361–372. https://doi.org/10.1002/path.1711760407

16. Sato T, Okazaki A, Okazaki M, et al (1995) Detection of p53 gene mutations in aspiration biopsy specimens from suspected breast cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 86:140–145. https://doi.org/10.1111/j.1349-7006.1995.tb03031.x

17. Thorlacius S, Thorgilsson B, Björnsson J, et al (1995) TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 31A:1856–1861. https://doi.org/10.1016/0959-8049(95)00399-4

18. Blaszyk H, Hartmann A, Tamura Y, et al (1996) Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene 13:2159–2166

19. Aas T, Børresen AL, Geisler S, et al (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811–814. https://doi.org/10.1038/nm0796-811

20. Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al (1996) TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 74:555–561. https://doi.org/10.1038/bjc.1996.400

21. Hartmann A, Blaszyk H, Saitoh S, et al (1996) High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer 73:896–901. https://doi.org/10.1038/bjc.1996.179

22. Kovach JS, Hartmann A, Blaszyk H, et al (1996) Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A 93:1093–1096. https://doi.org/10.1073/pnas.93.3.1093

23. Chakravarty G, Redkar A, Mittra I (1996) A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer 74:1181–1187. https://doi.org/10.1038/bjc.1996.514

24. Lou MA, Tseng SL, Chang SF, et al (1997) Novel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area. Br J Cancer 75:746–751. https://doi.org/10.1038/bjc.1997.132

25. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, et al (1997) Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105:121–130. https://doi.org/10.1111/j.1699-0463.1997.tb00550.x

26. Zelada-Hedman M, Børresen-Dale AL, Claro A, et al (1997) Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 75:1201–1204. https://doi.org/10.1038/bjc.1997.205

27. Günther T, Schneider-Stock R, Rys J, et al (1997) p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J Cancer Res Clin Oncol 123:388–394. https://doi.org/10.1007/BF01240122

28. Berns EM, van Staveren IL, Look MP, et al (1998) Mutations in residues of TP53 that directly

contact DNA predict poor outcome in human primary breast cancer. Br J Cancer 77:1130–1136. https://doi.org/10.1038/bjc.1998.187

29. Lavarino C, Corletto V, Mezzelani A, et al (1998) Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer 77:125–130. https://doi.org/10.1038/bjc.1998.20

30. Williams C, Norberg T, Ahmadian A, et al (1998) Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem 44:455–462

31. Wernert N, Hügel A, Löcherbach C (1998) [Genetic alterations in the fibroblastic stroma of invasive colon and breast carcinomas]. Verh Dtsch Ges Pathol 82:317–321

32. Kucera E, Speiser P, Gnant M, et al (1999) Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 35:398–405. https://doi.org/10.1016/s0959-8049(98)00400-6

33. Gentile M, Bergman Jungeström M, Olsen KE, et al (1999) p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 35:1202–1207. https://doi.org/10.1016/s0959-8049(99)00121-5

34. Tanyi J, Tory K, Bánkfalvi A, et al (1999) Analysis of p53 mutation and cyclin D1 expression in breast tumors. Pathol Oncol Res 5:90–94. https://doi.org/10.1053/paor.1999.0201

35. Tomita S, Muto Y, Kusano T, Toda T (1999) [Genetic alterations in human malignant tumor]. Rinsho Byori 47:20–26

36. Patrinos GP, Garinis G, Kounelis S, et al (1999) A novel 23-bp deletion in exon 5 of the p53 tumor suppressor gene. J Mol Med (Berl) 77:686–689. https://doi.org/10.1007/s001099900043

37. Maitra A, Tavassoli FA, Albores-Saavedra J, et al (1999) Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol 30:1435–1440. https://doi.org/10.1016/s0046-8177(99)90165-x

38. Alsner J, Yilmaz M, Guldberg P, et al (2000) Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin cancer Res an Off J Am Assoc Cancer Res 6:3923–3931. https://doi.org/10.1186/bcr109

39. Angelopoulou K, Yu H, Bharaj B, et al (2000) p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 33:53–62. https://doi.org/10.1016/s0009-9120(99)00084-3

40. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin cancer Res an Off J Am Assoc Cancer Res 6:50–56

41. Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, et al (2000) P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol 22:268–274. https://doi.org/10.1002/(sici)1097-0339(200005)22:5<268::aid-dc2>3.0.co;2-x

42. Oh SJ, Jung JY, Shim SS, et al (2000) Identification of p53 gene mutations in breast cancers and

their effects on transcriptional activation function. Mol Cells 10:275–280

43. Kannan K, Krishnamurthy J, Feng J, et al (2000) Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas. Int J Oncol 17:1031–1035. https://doi.org/10.3892/ijo.17.5.1031

44. Kang JH, Kim SJ, Noh DY, et al (2001) The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J Mol Med (Berl) 79:648–655. https://doi.org/10.1007/s001090100269

45. Geisler S, Lønning PE, Aas T, et al (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61:2505–2512

46. Janschek E, Kandioler-Eckersberger D, Ludwig C, et al (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67:1–8. https://doi.org/10.1023/a:1010661514306

47. Buzin CH, Tang SH, Cunningham JM, et al (2001) Low frequency of p53 gene mutations in breast cancers of Japanese-American women. Nutr Cancer 39:72–77. https://doi.org/10.1207/S15327914nc391_10

48. Kang JH, Kim SJ, Noh DY, et al (2001) Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma. Lab Invest 81:573–579. https://doi.org/10.1038/labinvest.3780266

49. Stenmark-Askmalm M, Gentile M, Wingren S, Ståhl O (2001) Protein accumulation and gene mutation of p53 in bilateral breast cancer. South-East Sweden Breast Cancer Group. Acta Oncol 40:56–62. https://doi.org/10.1080/028418601750071064

50. Wang X, Mori I, Tang W, et al (2001) Metaplastic carcinoma of the breast: p53 analysis identified the same point mutation in the three histologic components. Mod Pathol an Off J United States Can Acad Pathol Inc 14:1183–1186. https://doi.org/10.1038/modpathol.3880456

51. Conway K, Edmiston SN, Cui L, et al (2002) Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 62:1987–1995

52. Langerød A, Bukholm IRK, Bregård A, et al (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol 11:1684–1688

53. Tessitore A, Di Rocco ZC, Cannita K, et al (2002) High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. Genes Chromosomes Cancer 35:86–91. https://doi.org/10.1002/gcc.10102

54. Seitz S, Wassmuth P, Fischer J, et al (2002) Mutation analysis and mRNA expression of trail-receptors in human breast cancer. Int J cancer 102:117–128. https://doi.org/10.1002/ijc.10694

55. Nagai MA, Schaer Barbosa H, Zago MA, et al (2003) TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol 23:189–196

56. Bukholm IRK, Husdal A, Nesland JM, et al (2003) Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. Breast Cancer Res Treat 80:199–206. https://doi.org/10.1023/A:1024527220362

57. Geisler S, Børresen-Dale A-L, Johnsen H, et al (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin cancer Res an Off J Am Assoc Cancer Res 9:5582–5588

58. Sekido Y, Umemura S, Takekoshi S, et al (2003) Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol 22:1225–1232

59. Sensi E, Tancredi M, Aretini P, et al (2003) p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 82:1–9. https://doi.org/10.1023/B:BREA.0000003836.91844.b5

60. Reifenberger J, Rauch L, Beckmann MW, et al (2003) Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol 148:1040–1046. https://doi.org/10.1046/j.1365-2133.2003.05322.x

61. Chen F-M, Hou M-F, Wang J-Y, et al (2004) High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan. Cancer Lett 207:59–67. https://doi.org/10.1016/j.canlet.2003.12.005

62. Jong Y-J, Li L-H, Tsou M-H, et al (2004) Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 148:55–65. https://doi.org/10.1016/s0165-4608(03)00205-x

63. Lien H-C, Lin C-W, Mao T-L, et al (2004) p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol 204:131–139. https://doi.org/10.1002/path.1624

64. Hedau S, Jain N, Husain SA, et al (2004) Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 88:177–186. https://doi.org/10.1007/s10549-004-0593-8

65. Lord GM, Hollstein M, Arlt VM, et al (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J kidney Dis Off J Natl Kidney Found 43:e11-7. https://doi.org/10.1053/j.ajkd.2003.11.024

66. Kleivi K, Diep CB, Pandis N, et al (2005) TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. J Pathol 207:14–19. https://doi.org/10.1002/path.1812

67. Kalemi TG, Lambropoulos AF, Gueorguiev M, et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65. https://doi.org/10.1016/j.canlet.2004.11.025

68. Olivier M, Langerød A, Carrieri P, et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-05-1029

69. Boersma BJ, Howe TM, Goodman JE, et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911–919. https://doi.org/10.1093/jnci/djj245

70. Han B, Mori I, Nakamura M, et al (2006) Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis. Pathol Int 56:211–216. https://doi.org/10.1111/j.1440-1827.2006.01948.x

71. Langerød A, Zhao H, Borgan Ø, et al (2007) TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9:R30. https://doi.org/10.1186/bcr1675

72. Ooe A, Kato K, Noguchi S (2007) Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101:305–315. https://doi.org/10.1007/s10549-006-9293-x

73. Patocs A, Zhang L, Xu Y, et al (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357:2543–2551. https://doi.org/10.1056/NEJMoa071825

74. Eachkoti R, Hussain I, Afroze D, et al (2007) BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Lett 248:308–320. https://doi.org/10.1016/j.canlet.2006.08.012

75. Xu Y, Yao L, Zhao A, et al (2008) Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J cancer 122:2761–2766. https://doi.org/10.1002/ijc.23454

76. Chrisanthar R, Knappskog S, Løkkevik E, et al (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 3:e3062. https://doi.org/10.1371/journal.pone.0003062

77. Suspitsin EN, Due EU, Vu P, et al (2008) TP53 mutations in synchronous and metachronous bilateral breast carcinomas. Cancer Genet. Cytogenet. 184:119–121

78. Colombo M, Giarola M, Mariani L, et al (2008) Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Mod Pathol an Off J United States Can Acad Pathol Inc 21:1262–1270. https://doi.org/10.1038/modpathol.2008.43

79. Zhou W, Muggerud AA, Vu P, et al (2009) Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution. Mol Oncol 3:214–219. https://doi.org/10.1016/j.molonc.2009.03.001

80. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412

81. Banerji S, Cibulskis K, Rangel-Escareno C, et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405–409. https://doi.org/10.1038/nature11154

82. Stephens PJ, Tarpey PS, Davies H, et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404. https://doi.org/10.1038/nature11017

83. Pereira B, Chin S-F, Rueda OM, et al (2016) The somatic mutation profiles of 2,433 breast cancers

refines their genomic and transcriptomic landscapes. Nat Commun 7:11479. https://doi.org/10.1038/ncomms11479

84. Li G, Guo X, Chen M, et al (2018) Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. PLoS One 13:e0203495. https://doi.org/10.1371/journal.pone.0203495

85. Kan Z, Ding Y, Kim J, et al (2018) Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun 9:1725. https://doi.org/10.1038/s41467-018-04129-4

86. Yap Y-S, Singh AP, Lim JHC, et al (2018) Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. NPJ breast cancer 4:19. https://doi.org/10.1038/s41523-018-0070-x

87. Heong V, Syn NL, Lee XW, et al (2018) Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. Int J cancer 142:1890–1900. https://doi.org/10.1002/ijc.31091

88. Zhang G, Wang Y, Chen B, et al (2019) Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Ann Transl Med. https://doi.org/10.21037/atm.2019.04.23

89. Wang S, Pitt JJ, Zheng Y, et al (2019) Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J cancer 145:3321–3333. https://doi.org/10.1002/ijc.32498

90. Yi D, Xu L, Luo J, et al (2019) Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study. Hum Genomics 13:4. https://doi.org/10.1186/s40246-018-0186-y

91. Chang C-S, Kitamura E, Johnson J, et al (2019) Genomic analysis of racial differences in triple negative breast cancer. Genomics 111:1529–1542. https://doi.org/10.1016/j.ygeno.2018.10.010

92. Powers J, Pinto EM, Barnoud T, et al (2020) A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Res 80:3732–3744. https://doi.org/10.1158/0008-5472.CAN-20-1390

93. Bouaoun L, Sonkin D, Ardin M, et al (2016) TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. https://doi.org/10.1002/humu.23035

94. Slovackova J, Grochova D, Navratilova J, et al (2010) Transactivation by temperature-dependent p53 mutants in yeast and human cells. Cell Cycle 9:2141–2148. https://doi.org/10.4161/cc.9.11.11808

95. Jordan JJ, Inga A, Conway K, et al (2010) Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res 8:701–716. https://doi.org/10.1158/1541-7786.MCR-09-0442

96. Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN (2017) [Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma]. Mol Biol (Mosk) 51:64–72. https://doi.org/10.7868/S0026898416060227

97. Li C-L, Yeh K-H, Liu W-H, et al (2015) Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-α in female hepatocellular carcinoma. Int J cancer 136:761–770. https://doi.org/10.1002/ijc.29052

98. Gonin-Laurent N, Gibaud A, Huygue M, et al (2006) Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis 27:1266–1272. https://doi.org/10.1093/carcin/bgi356

99. O'Farrell TJ, Ghosh P, Dobashi N, et al (2004) Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 64:8199–8207. https://doi.org/10.1158/0008-5472.CAN-03-3639

100. Christgen M, Noskowicz M, Heil C, et al (2012) IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. Lab Invest 92:1635–1647. https://doi.org/10.1038/labinvest.2012.126

101. Göhler T, Jäger S, Warnecke G, et al (2005) Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 33:1087–1100. https://doi.org/10.1093/nar/gki252

102. Bartussek C, Naumann U, Weller M (1999) Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Exp Cell Res 253:432–439. https://doi.org/10.1006/excr.1999.4654

103. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A 103:15056–15061. https://doi.org/10.1073/pnas.0607286103

104. Kang HJ, Chun S-M, Kim K-R, et al (2013) Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One 8:e72609. https://doi.org/10.1371/journal.pone.0072609

105. Monti P, Campomenosi P, Ciribilli Y, et al (2003) Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene 22:5252–5260. https://doi.org/10.1038/sj.onc.1206511

106. Marutani M, Tonoki H, Tada M, et al (1999) Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59:4765–4769

107. Barta JA, Pauley K, Kossenkov A V, McMahon SB (2020) The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. Carcinogenesis 41:67–77. https://doi.org/10.1093/carcin/bgz087

108. Cardellino U, Ciribilli Y, Andreotti V, et al (2007) Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach. Mutagenesis 22:417–423. https://doi.org/10.1093/mutage/gem038

109. Yamamoto S, Iwakuma T (2018) Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel) 11:. https://doi.org/10.3390/cancers11010004

110. Berge EO, Huun J, Lillehaug JR, et al (2013) Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochim Biophys Acta 1830:2790–2797. https://doi.org/10.1016/j.bbagen.2012.12.004

111. Xie X, Lozano G, Siddik ZH (2016) Heterozygous p53(V172F) mutation in cisplatin-resistant human

tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene 35:4798–4806. https://doi.org/10.1038/onc.2016.12

112. Ryan KM, Vousden KH (1998) Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692–3698. https://doi.org/10.1128/mcb.18.7.3692

113. Solomon H, Buganim Y, Kogan-Sakin I, et al (2012) Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci 125:3144–3152. https://doi.org/10.1242/jcs.099663

114. West AN, Ribeiro RC, Jenkins J, et al (2006) Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res 66:5056–5062. https://doi.org/10.1158/0008-5472.CAN-05-4580

115. Xu-Monette ZY, Wu L, Visco C, et al (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 120:3986–3996. https://doi.org/10.1182/blood-2012-05-433334

116. Mullany LK, Wong K-K, Marciano DC, et al (2015) Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival. Neoplasia 17:789–803. https://doi.org/10.1016/j.neo.2015.10.003

117. Kato S, Han S-Y, Liu W, et al (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100:8424–8429. https://doi.org/10.1073/pnas.1431692100

118. Ahn J, Poyurovsky M V, Baptiste N, et al (2009) Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle 8:1603–1615. https://doi.org/10.4161/cc.8.10.8548

119. Martynova E, Pozzi S, Basile V, et al (2012) Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 3:132–143. https://doi.org/10.18632/oncotarget.447

120. Suchánková J, Legartová S, Ručková E, et al (2017) Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after γ-irradiation that depleted MDC1 protein in specific TP53 mutants. Histochem Cell Biol 148:239–255. https://doi.org/10.1007/s00418-017-1567-3

121. Ticha I, Hojny J, Michalkova R, et al (2019) A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants. Sci Rep 9:17050. https://doi.org/10.1038/s41598-019-53636-x

122. Lai J-C, Cheng Y-W, Goan Y-G, et al (2008) Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. DNA Repair (Amst) 7:1352–1363. https://doi.org/10.1016/j.dnarep.2008.04.016

123. Friedler A, Veprintsev DB, Hansson LO, Fersht AR (2003) Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem 278:24108–24112. https://doi.org/10.1074/jbc.M302458200

124. Tsuchiya K (2000) [Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant]. Hokkaido Igaku Zasshi 75:265–274

125. Dong P, Tada M, Hamada J-I, et al (2007) p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis 24:471–483. https://doi.org/10.1007/s10585-007-9084-8

126. Jia LQ, Osada M, Ishioka C, et al (1997) Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 19:243–253. https://doi.org/10.1002/(sici)1098-2744(199708)19:4<243::aid-mc5>3.0.co;2-d

127. Pavlova S, Mayer J, Koukalova H, Smardova J (2003) High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast. Int J Oncol 23:121–131

128. Zerdoumi Y, Lanos R, Raad S, et al (2017) Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Hum Mol Genet 26:2591–2602. https://doi.org/10.1093/hmg/ddx106

129. Yu X, Blanden AR, Narayanan S, et al (2014) Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5:8879–8892. https://doi.org/10.18632/oncotarget.2432

130. Liu S, Kumari S, Hu Q, et al (2017) A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife 6:. https://doi.org/10.7554/eLife.28482

131. Jia S, Zhao L, Tang W, Luo Y (2012) The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int J Biol Sci 8:596–605. https://doi.org/10.7150/ijbs.4176

132. Lokshin M, Li Y, Gaiddon C, Prives C (2007) p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res 35:340–352. https://doi.org/10.1093/nar/gkl1047

133. Davies AJ, Lee AM, Taylor C, et al (2005) A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 19:1459–1465. https://doi.org/10.1038/sj.leu.2403802

134. Kramer AC, Weber J, Zhang Y, et al (2017) TP53 Modulates Oxidative Stress in Gata1(+) Erythroid Cells. Stem cell reports 8:360–372. https://doi.org/10.1016/j.stemcr.2016.12.025

135. Quinn EA, Maciaszek JL, Pinto EM, et al (2019) From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Cold Spring Harb Mol case Stud 5:. https://doi.org/10.1101/mcs.a003921

136. Jagosova J, Pitrova L, Slovackova J, et al (2012) Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells. Int J Oncol 41:1157–1163. https://doi.org/10.3892/ijo.2012.1520

137. Nenutil R, Smardova J, Pavlova S, et al (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259.

https://doi.org/10.1002/path.1838

138. Fulci G, Ishii N, Maurici D, et al (2002) Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res 62:2897–2905

139. Vaughan CA, Frum R, Pearsall I, et al (2012) Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem Biophys Res Commun 428:6–10. https://doi.org/10.1016/j.bbrc.2012.09.029

140. Dearth LR, Qian H, Wang T, et al (2007) Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28:289–298. https://doi.org/10.1093/carcin/bgl132

141. Li J, Yang L, Gaur S, et al (2014) Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum Mutat 35:575–584. https://doi.org/10.1002/humu.22528

142. Ko J-L, Chiao M-C, Chang S-L, et al (2002) A novel p53 mutant retained functional activity in lung carcinomas. DNA Repair (Amst) 1:755–762. https://doi.org/10.1016/s1568-7864(02)00094-0

143. Di Como CJ, Prives C (1998) Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16:2527–2539. https://doi.org/10.1038/sj.onc.1202041

144. Buzek J, Latonen L, Kurki S, et al (2002) Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 30:2340–2348. https://doi.org/10.1093/nar/30.11.2340

145. Noureddine MA, Menendez D, Campbell MR, et al (2009) Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. PLoS Genet 5:e1000462. https://doi.org/10.1371/journal.pgen.1000462

146. Wang B, Niu D, Lam TH, et al (2014) Mapping the p53 transcriptome universe using p53 natural polymorphs. Cell Death Differ 21:521–532. https://doi.org/10.1038/cdd.2013.132

147. Menendez D, Inga A, Resnick MA (2006) The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 26:2297–2308. https://doi.org/10.1128/MCB.26.6.2297-2308.2006

148. Zhou R, Xu A, Wang D, et al (2018) A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. Stem Cell Res 27:131–135. https://doi.org/10.1016/j.scr.2018.01.035

149. Lang V, Pallara C, Zabala A, et al (2014) Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Mol Oncol 8:1026–1042. https://doi.org/10.1016/j.molonc.2014.04.002

150. Kamada R, Nomura T, Anderson CW, Sakaguchi K (2011) Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem 286:252–258. https://doi.org/10.1074/jbc.M110.174698

151. Kawaguchi T, Kato S, Otsuka K, et al (2005) The relationship among p53 oligomer formation,

structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24:6976–6981. https://doi.org/10.1038/sj.onc.1208839